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Antimicrobial metaphylaxis is an important tool used for the prevention of Bovine Respiratory Disease 
Complex; a disease with a large economic impact that typically affects newly-weaned beef calves that are 
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to activate an animal’s natural immunity to fight Bovine Respiratory Disease Complex, being used either 
solely or in combination with metaphylaxis at the time of initial processing of high risk calves. More 
knowledge is also needed regarding the possible effects of repeated use of Zelnate when subsequent 
therapy is required in individual Bovine Respiratory Disease Complex cases. The objective of this study 
was to evaluate the effectiveness of Zelnate when used as part of an antimicrobial metaphylaxis 
treatment or when used in combination with an antibiotic when a calf is diagnosed with Bovine 
Respiratory Disease Complex. 
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Zelnate on Arrival Could Decrease the 
Likelihood of Subsequent Pulls in Suspect 
Bovine Respiratory Disease Complex Cases
T.J. Spore, S.P. Montgomery, G.A. Hanzlicek, W.R. Hollenbeck, R.N. Wahl, 
J.E. Sears1, and D.A. Blasi
Introduction
Antimicrobial metaphylaxis is an important tool used for the prevention of Bovine 
Respiratory Disease Complex; a disease with a large economic impact that typically af-
fects newly-weaned beef calves that are marketed and transported a distance from their 
origin. 
There are questions involving the potential benefit of Zelnate, a novel non-antibiotic 
technology designed to activate an animal’s natural immunity to fight Bovine Respira-
tory Disease Complex, being used either solely or in combination with metaphylaxis at 
the time of initial processing of high risk calves. More knowledge is also needed regard-
ing the possible effects of repeated use of Zelnate when subsequent therapy is required 
in individual Bovine Respiratory Disease Complex cases. The objective of this study was 
to evaluate the effectiveness of Zelnate when used as part of an antimicrobial metaphy-
laxis treatment or when used in combination with an antibiotic when a calf is diagnosed 
with Bovine Respiratory Disease Complex. 
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Experimental Procedures
During a four-day period (October 6-9, 2015) three semi-loads containing 283 head of 
high-risk cross-bred heifers (520 ± 39 lb) were purchased from sale barns in Tennes-
see and Alabama, assembled at a Dickson, Tennessee order buyer facility, and shipped 
to the Kansas State University Beef Stocker Unit. After initial processing the animals 
were placed in temporary pens with each truck representing six pens with free access to 
native grass hay and water through automatic waterers. The morning after arrival, calves 
were vaccinated for common clostridial and viral diseases (Pyramid 5 + Presponse, 
Vetmedica, St. Joseph, MO; Excede, Zoetis, Parsippany, NJ; Vison 7 with Somnus, 
Merck Animal Health, Madison, NJ); dewormed (Safeguard, Merck Animal Health, 
Madison, NJ); treated for flies (Permectrin CDS; Bayer, Shawnee Mission, KS); and 
implanted with a mild growth implant (Revalor IH, Merck Animal Health, Madison, 
1 Bayer Health Care, LLC, Animal Health.
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NJ). One half of the calves also received 2 ml intramuscular of Zelnate (Bayer Health-
care, Animal Health Division, Shawnee Mission, KS) at this time. Calves were blocked 
by load and initially assigned to six pens based on arrival weight. To maintain similar 
weights between initial treatments (receiving Zelnate or not at arrival), after animals 
were sorted by weight, the heaviest animal in the pen was assigned group no Zelnate 
and the next heaviest group received Zelnate at initial processing. This procedure was 
replicated through each pen to standardize weights between arrival groups. A second 
population of treatments was generated based on rectal temperature as the animals were 
visually pulled for illness. Calves that had a rectal temperature of greater than or equal 
to 104°F at first pull received Baytril 100 (Bayer Healthcare, Animal Health Division, 
Shawnee Mission, KS) (Bovine Respiratory Disease, no Zelnate at pull) or Baytril 100 
and Zelnate (Bovine Respiratory Disease, Zelnate at pull). Similarly, calves that did not 
have a rectal temperature of 104°F were either not treated at all (respiratory observed, 
no Zelnate) or administered only Zelnate (respiratory observed, Zelnate). The combi-
nation of treatment group on arrival and treatment at first pull for illness yielded eight 
possible treatments for cattle that were pulled and two for cattle that were never pulled. 
All animals enrolled in the study were fed an identical diet once daily at approximately 
7:00 a.m. (Table 1). Feed bunks were checked once daily and adjustments made in 
delivery to ensure feed bunks were slick at the next feeding. All calves were checked at 
least once daily to assess animal health. Performance data were analyzed using standard 
T-test for mean comparison and ANOVA in StatPlus (Version 6; AnalystSoft Inc.). 
Health data were analyzed using proportion comparisons of morbidity in Stata 12 
(StataCorp., 2011). 
Results and Discussion
The results from the study are below in Tables 2, 3, 4, and 5. The administration of Zel-
nate upon arrival had no statistical effect on initial pull (P=0.92) or average daily gain 
(P=0.34). Although there were no statistical differences in morbidity 2 (second pull) 
between any of the treatments, calves that received Zelnate on arrival but not at first 
treatment for suspect cases of Bovine Respiratory Disease Complex (Zelnate at arrival, 
respiratory observed, no Zelnate at pull) appeared to be less likely to experience subse-
quent pulls compared to those animals receiving Zelnate only at treatment for Bovine 
Respiratory Disease Complex (no Zelnate at arrival, respiratory observed, Zelnate at 
pull) (P=0.06). Furthermore, average daily gain of calves that received Zelnate on ar-
rival and not as a component of Bovine Respiratory Disease Complex therapy (Zelnate 
at arrival, no Zelnate at pull) appeared to be higher; however, the difference was not 
statistically significant (P=0.8). 
Implications
These results suggest that Zelnate used only in combination with metaphylaxis on ar-
rival and not as a component of Bovine Respiratory Disease Complex treatment could 
decrease the likelihood of additional pulls in suspect Bovine Respiratory Disease Com-
plex cases. Additional research opportunities may exist in addressing the effectiveness of 
Zelnate used as pre-shipping treatment, particularly as calves are loaded on trucks at the 
order buyer/auction market facilities prior to transportation. 
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Table 1. Experimental diet fed
Experimental diet % of dry matter
Ingredient





Corn germ meal 11.25
Distillers dried grains 10.00
Total 100.00
Calculated nutrient content








Acid detergent fiber, % 18.22
Net energy gain, Mcal/cwt 48.68
Table 2. Proportion of calves initially pulled for illness from each treatment
Arrival treatment 1st pull rate P-value
No Zelnate 39% 0.92
Received Zelnate at initial processing 39%
Table 3. Healthy cattle performance
Arrival treatment Final average daily gain, lb P-value
No Zelnate 3.23 0.34
Received Zelnate at initial processing 3.27
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Table 4. Proportion of calves pulled twice from each treatment combination
Bovine Respiratory Disease cases 2nd pull rate
No Zelnate at arrival / no Zelnate at first pull 35%
No Zelnate at arrival / Zelnate given at first pull 54%
Zelnate at arrival / no Zelnate at first pull 44%
Zelnate at arrival / Zelnate given at first pull 33%
Respiratory observed, no fever cases 2nd pull rate
No Zelnate at arrival / no Zelnate at first pull 44%ab
No Zelnate at arrival / Zelnate given at first pull 50%a
Zelnate at arrival / no Zelnate at first pull 11%b
Zelnate at arrival / Zelnate given at first pull 36%ab
ab Means in a column with uncommon superscripts differ.
Table 5. Morbid cattle performance
Arrival treatment/pull treatment Final average daily gain, lb P-value
No Zelnate at arrival / no Zelnate at first pull 2.73 0.80
No Zelnate at arrival / Zelnate given at first pull 2.46
Zelnate at arrival / no Zelnate at first pull 2.86
Zelnate at arrival / Zelnate given at first pull 2.71
